PATIENTS AND METHODS
This work is an observational study on all patients treated with HCQ for
COVID-19 infection in medicine care services of the Bordeaux university
hospital. Prescriptions and baseline characteristics were analyzed
during four weeks.
The analysis of DDIs was focused on cardiovascular side effects,
especially QT prolongation or Torsades de Pointe (TdP). For each drug,
we assessed the risk of prolonging the QT interval and causing
arrhythmia by using two publicly available reference sites:
CredibleMeds.org and french-drugs database
Thériaque®11. Thus, these drugs were divided into four
broad categories: drugs contraindicated with HCQ (drugs associated with
a known risk of QT prolongation or TdP), drugs not recommended with HCQ
(drugs associated with a possible risk of QT prolongation), drugs that
do not prolong the QT interval per se but can create clinical or
biological conditions that facilitate or induce QT-prolongation
(bradycardia or hypokalemia) and drugs without impact on
QT-prolongation. We also analyzed how these DDIs were managed.